DiaSorin SpA (DIA.MI) stock: key figures, P/E, revenue and dividend

Health Care · Italy · ISIN IT0003492391

Price
78.16 EUR
Market cap
4.27 bn EUR
P/E (2025)
28.47
P/S (2025)
3.57
Dividend yield
1.66 %
Net margin
12.97 %
Return on equity (ROE)
9.78 %
Return on assets (ROA)
5.39 %

DiaSorin SpA financials

Fiscal year20242025
Revenue1.19 bn EUR1.20 bn EUR
Gross profit781.00 m EUR699.00 m EUR
Operating income266.21 m EUR274.67 m EUR
EBIT258.00 m EUR304.00 m EUR
Net income188.00 m EUR155.00 m EUR
Diluted EPS – continuing operations3.35 EUR2.75 EUR

Full history since 2003, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About DiaSorin SpA

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.

DiaSorin SpA stock (DIA.MI): P/E, revenue, dividend | finmetric